Long-term Outcome of DBS Versus Botulinum Toxin Treatment in Cervical Dystonia
Launched by OSLO UNIVERSITY HOSPITAL · Jun 12, 2020
Trial Information
Current as of July 25, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Cervical dystonia (CD) is the most common isolated dystonia in adults, with a prevalence of 9-13/100000. CD has a mean age at onset of 40 years, and is almost twice as common in women than in men. Cervical dystonia symptoms can in most patients be managed well by botulinum toxin (BoNT) injections, and supporting treatment measures. However, one-fifth to one-third of patients do not obtain sufficient relief from long-term BoNT therapy, resulting in reduced quality of life. Deep brain stimulation in the postero-ventral part of the internal globus pallidus (GPi-DBS) has been established as an ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • DBS-group: Patients with isolated cervical dystonia (focal or part of segmental dystonia) who have been operated at Oslo University between June 2004 and June 2017 and treated with bilateral GPi-DBS for a minimum of 3 years, and who give their informed consent to participate in this follow-up study.
- • BoNT-group: Patients who are receiving regular BoNT-injections at Oslo University Hospital for isolated cervical dystonia (focal or part of segmental dystonia), who are gender-and age-matched to the operated patients, and who give their informed consent to participate in this follow-up study.
- Exclusion Criteria:
- • Dementia/inability to respond to the CDIP-58.
About Oslo University Hospital
Oslo University Hospital is a leading academic medical center in Norway, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, the hospital integrates cutting-edge scientific inquiry with patient care, fostering an environment that promotes the development of new therapies and treatment strategies. With a multidisciplinary approach, Oslo University Hospital collaborates with various stakeholders, including researchers, healthcare professionals, and industry partners, to enhance clinical outcomes and contribute to the global medical community. Its dedication to ethical standards and patient safety ensures that all trials are conducted with the highest level of integrity and respect for participant welfare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Oslo, , Norway
Patients applied
Trial Officials
Inger Marie Skogseid, MDPhD
Study Director
Oslo University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials